Breaking News, Collaborations & Alliances

RCSI and Almac Discovery Enter Research Collaboration

Will target therapy-resistant cancer tumors; research has potential to improve 20 percent survival rate in ovarian cancer

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

RCSI (Royal College of Surgeons in Ireland) and Almac Discovery have formed a research collaboration that aims to gain a new understanding of how to target tumor cells that are resistant to cancer therapies and cause cancer to spread to other parts of the body. The project will explore the potential of a drug, based on initial research by RCSI’s Professor Tracy Robson and developed by Almac Discovery, which is currently undergoing a Phase I dose escalation trial for patients with solid tumors. I...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters